Upon completion of the acquisition, Eyeonics’s operations will become part of Bausch & Lomb’s surgical business, which offers a complete line of standard intraocular lenses, phacoemulsification equipment, vitreoretinal and refractive products to ophthalmologists worldwide. The US surgical business will be led by Andy Corley, Eyeonics’s co-founder, chairman, and CEO.
Ronald Zarrella, chairman and CEO, Bausch & Lomb, said: “This acquisition immediately places Bausch & Lomb into the rapidly expanding premium intraocular lens (IOL) market. The crystalens technology complements our existing cataract surgical business, including our Stellaris Vision Enhancement System and our portfolio of monofocal IOLs.”